2022

  1. Mirikizumab phase 2 in CD

  2. Safety and tolerability of spesolimab in UC

  3. Steroid exposure and perinatal outcomes

  4. Vedolizumab in perianal CD

  5. Low-dose azathioprine and allopurinol in UC

  6. Obefazimod in mod-severe UC

  7. Risankizumab maintenance of remission in CD